Infliximab treatment maintains employability in patients with early rheumatoid arthritis

Arthritis and Rheumatism
Josef S SmolenE William St Clair

Abstract

To evaluate the impact of infliximab therapy on the employment status of patients with early rheumatoid arthritis (RA). Methotrexate (MTX)-naive patients with active early RA were randomly allocated to receive MTX plus placebo or MTX plus infliximab (3 mg/kg or 6 mg/kg) at weeks 0, 2, and 6 and then every 8 weeks through week 46. Data for patients younger than age 65 years were included in the analyses. A patient was categorized as employable if he or she was employed or felt well enough to work if a job were available. The change in actual employment was not significantly different between patients receiving MTX plus infliximab and those receiving MTX plus placebo (0.5% versus 1.3%; P > 0.5). However, the proportion of patients whose status changed from employable at baseline to unemployable at week 54 was smaller in the group receiving MTX plus infliximab compared with that in the group receiving MTX alone (8% versus 14%; P = 0.05). Patients who were treated with infliximab plus MTX had a significantly greater likelihood of improvement rather than deterioration in employability (odds ratio 2.4; P < 0.001); this likelihood was not significantly greater in patients receiving MTX alone. The proportion of employed patients who lo...Continue Reading

References

Sep 1, 1992·Arthritis Care and Research : the Official Journal of the Arthritis Health Professions Association·D R RameyJ F Fries
May 1, 1987·Arthritis and Rheumatism·E YelinW Epstein
Jun 1, 1995·Annals of the Rheumatic Diseases·D DoeglasM van Rijswijk
Feb 20, 1999·Arthritis and Rheumatism·G KobeltB Jönsson
Mar 13, 1999·Annals of Internal Medicine·L W MorelandM E Weinblatt
May 11, 2000·Seminars in Arthritis and Rheumatism·K M PugnerK Hieke
Nov 30, 2000·The New England Journal of Medicine·P E LipskyUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
Aug 15, 2002·Annals of the Rheumatic Diseases·H M LapsleyUNKNOWN Arthritis Cost and Outcome Project Group
Aug 2, 2003·Schizophrenia Research·Rahul GangulyBradley C Martin
Nov 25, 2003·Scandinavian Journal of Rheumatology·M K SöderlinM Leirisalo-Repo
Dec 11, 2003·Journal of Rehabilitation Medicine·Roland Melin, Axel R Fugl-Meyer
Jan 15, 2004·Annals of the Rheumatic Diseases·F C BreedveldR N Maini
Feb 14, 2004·Annals of the Rheumatic Diseases·J S Smolen, D Aletaha
Mar 6, 2004·Lancet·Lars KlareskogUNKNOWN TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators
Jun 10, 2004·Arthritis and Rheumatism·S M M VerstappenUNKNOWN Utrecht Rheumatoid Arthritis Cohort Study Group
Nov 6, 2004·Arthritis and Rheumatism·E William St ClairUNKNOWN Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Grou

❮ Previous
Next ❯

Citations

Dec 12, 2012·Zeitschrift für Rheumatologie·M Frank, T Mittendorf
Mar 2, 2011·Clinical Rheumatology·Wei Zhang, Aslam H Anis
Dec 25, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·J Smolen, D Aletaha
Dec 10, 2013·Best Practice & Research. Clinical Rheumatology·Suzanne M M Verstappen
Jan 1, 2012·BoneKEy Reports·Lucia D'Amico, Ilaria Roato
Feb 7, 2007·Current Opinion in Rheumatology·Edward Yelin
Apr 7, 2007·Current Opinion in Rheumatology·Kate L Mitchell, David S Pisetsky
Apr 7, 2007·Current Opinion in Rheumatology·Arthur Kavanaugh
Apr 5, 2008·Current Opinion in Rheumatology·Hernan Castro-Rueda, Arthur Kavanaugh
Apr 4, 2009·Current Opinion in Rheumatology·Tuulikki Sokka
Mar 14, 2012·Current Opinion in Rheumatology·Minyoung Her, Arthur Kavanaugh
Feb 24, 2009·Arthritis Research & Therapy·Josef S Smolen, Daniel Aletaha
Jan 29, 2013·Journal of Multidisciplinary Healthcare·Hidekazu FuruyaRyo Takahashi
Jul 24, 2013·The Journal of Dermatological Treatment·Ethan C LevinJohn Koo
Jan 1, 2008·Journal of Medical Economics·Wayne N BurtonRoss Maclean
Dec 12, 2012·Best Practice & Research. Clinical Rheumatology·Wei ZhangAslam H Anis
Dec 6, 2011·Best Practice & Research. Clinical Rheumatology·Bruno FautrelAnnelies Boonen
Apr 1, 2009·Reumatología clinica·Jose L Marenco de la Fuente, Rocío Solís Díaz
Nov 20, 2008·Autoimmunity Reviews·Roberto CaporaliCarlomaurizio Montecucco
Sep 30, 2008·Arthritis and Rheumatism·Victoria BejaranoUNKNOWN Yorkshire Early Arthritis Register Consortium
Nov 28, 2015·Best Practice & Research. Clinical Rheumatology·Suzanne M M Verstappen
Nov 22, 2007·Expert Opinion on Therapeutic Targets·Christoph Ackermann, Arthur Kavanaugh
Feb 24, 2009·Best Practice & Research. Clinical Rheumatology·Nick BansbackAslam Anis
Nov 21, 2007·International Journal of Cardiology·Ignacio J Sánchez-LázaroAntonio Salvador

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.